Welcome to our dedicated page for Catheter Precision news (Ticker: VTAK), a resource for investors and traders seeking the latest updates and insights on Catheter Precision stock.
Catheter Precision, Inc. reports developments across cardiac electrophysiology medical devices and regional air mobility. The company’s medical technology updates center on VIVO, a non-invasive 3D imaging system for identifying ventricular arrhythmia origins before electrophysiology procedures, and LockeT, a suture retention device for wound closure after percutaneous venous punctures.
Recurring VTAK news also covers FDA and CE Mark status, clinical publications, medical conference activity, patent protection, product commercialization, and Flyte, its regional air mobility subsidiary. Flyte operates Cirrus Vision Jets for short-haul markets through an FAA-certified Part 135 air carrier platform.
Catheter Precision (VTAK) is expanding commercialization of its LockeT cardiac electrophysiology product across Latin America following a successful launch in Brazil in August 2026.
LockeT was introduced in São Paulo through a distribution agreement with Ablacor and is now used in six hospitals, with additional Brazilian institutions expressing interest. To support broader regional growth, the company has engaged an experienced cardiology group with electrophysiology expertise and longstanding relationships throughout Latin America. Catheter Precision is pursuing opportunities in Argentina, Chile, Colombia and other countries, viewing early Brazilian adoption as a model for its wider international expansion strategy.
Catheter Precision (VTAK) announced a New York Fashion Week partnership between Flyte and fashion designer Christian Cowan to grow the Flyte brand.
The collaboration aligns Flyte’s private aviation platform with Christian Cowan’s globally recognized fashion label and the high‑value audience surrounding New York Fashion Week, including celebrities, executives, creators and tastemakers. Flyte aims to build a lifestyle-focused private aviation brand by integrating into culturally relevant events and communities across fashion, entertainment, sports, hospitality and luxury travel, supported by a standardized Cirrus Vision Jet fleet, a direct-to-consumer technology platform and an expanding network of strategic partnerships.
Catheter Precision (VTAK) subsidiary Flyte has received international approvals to expand private flight operations from the United States into The Bahamas and Caribbean.
The authorization allows Flyte to offer private charter services linking its growing Florida network with high-demand leisure and resort destinations across the region, using its fleet of Cirrus Vision Jets. Initial potential routes include Miami, Fort Lauderdale, Palm Beach and Naples to locations such as Nassau, Bimini, Marsh Harbour and Eleuthera. Flyte plans immediate commercialization through direct-to-consumer marketing, strategic partnerships and its existing customer base.
Catheter Precision (NYSE American: VTAK) reported key commercial milestones for its cardiac electrophysiology portfolio, including its first purchase order for the LockeT suture retention device placed through Cardinal Health, which services roughly 90% of U.S. hospitals via its medical products business.
The company also received an initial LockeT order from Johns Hopkins Hospital, a leading academic medical center, and signed its first placement contract for the VIVO 3D imaging system with a hospital in Germany, one of Europe’s largest electrophysiology markets, supporting its U.S. distribution and international expansion strategy.
Flyte, a subsidiary of Catheter Precision (NYSE American: VTAK), reported surpassing 10,000 consumer accounts on its private aviation WebApp, with new account creation accelerating sharply. From August 1–17, Flyte added 1,830 accounts, up about 170% from the 679 accounts added in the same July period.
Over the most recent 30 days, Flyte added 2,417 accounts, an increase of roughly 118% versus the prior 30 days, and has added 3,132 accounts in the third quarter to date compared with 1,934 during the entire first half of 2026. Nearly one in four accounts was created in the last 30 days. According to Flyte, the more than 10,000 accounts represent first-party customer relationships spanning 174 airports in 19 states, with about 6,105 accounts (around 60%) including mobile phone numbers, and are supported by 14 strategic partners across multiple premium sectors.
Catheter Precision (NYSE American: VTAK), doing business as Flyte, announced a strategic partnership with FullPAC, an AI-powered political technology platform serving more than 5,000 campaigns, SuperPACs and political organizations. Flyte becomes FullPAC’s recommended regional aviation partner, offering its Cirrus Vision Jet network to qualified congressional, Senate, gubernatorial and attorney general campaigns.
The partnership targets the $11.4 billion U.S. political campaign market for the 2026 cycle, initially focusing on high-value statewide races in Florida, New York, Pennsylvania, North Carolina, Virginia and Georgia. According to Flyte, benefits include access to FullPAC’s nationwide network, time savings via regional airports, lower operating costs versus larger jets, and expanded utilization for Flyte’s Vision Jet fleet across business, leisure and political travel segments.
Flyte, a subsidiary of Catheter Precision (NYSE American: VTAK), announced a strategic partnership with The Nucleus Network, a fast-growing community for founders, investors, executives, and innovators. Flyte will support and participate in the inaugural “The Nucleus” flagship event on August 15 at 4:00 p.m..
The event is intended to become The Nucleus Network’s signature annual gathering, convening about 200 founders, investors, operators, and strategic partners for networking, brand activations, and relationship building. According to Flyte, this partnership aligns with its strategy to connect with influential entrepreneurial and venture communities while promoting its technology-enabled private aviation services and growing fleet of Cirrus Vision Jets.
Flyte, a subsidiary of Catheter Precision (NYSE American: VTAK), reported preliminary record monthly revenue of approximately $640,000 for July 2026, a 102% sequential increase over June, marking the strongest operating month in Flyte’s history as demand rises on its private aviation platform.
Since relaunching its direct-to-consumer platform, Flyte has added 2,700+ new users, supported by strategic partnerships, digital marketing, and influencer campaigns. In 2026 it expanded partnerships with Blade, Vaunt, Volato AI (NYSE American: SOAR), GSE Worldwide & Emiliano Grillo, LifeVac, and LDV at The Maidstone. Catheter Precision emphasized that June and July 2026 revenue figures are preliminary, unaudited estimates and remain subject to change.
Catheter Precision (NYSE American: VTAK), through its subsidiary Flyte, announced that Flyte has become the inaugural enterprise customer of Volato AI (NYSE American: SOAR), an aviation-focused enterprise artificial intelligence platform. The deployment is intended to support Flyte’s strategy of building a scalable regional private aviation platform using advanced technology and intelligent automation.
According to Catheter Precision, Volato AI is expected to assist Flyte across multiple operational workflows, including customer communications, charter sales support, flight quoting, crew coordination, maintenance scheduling, dispatch support, compliance assistance, document management, operational scheduling, and broader administrative workflow automation. Flyte expects AI to enhance customer responsiveness, automate repetitive tasks, increase employee productivity, and improve operating leverage as short-haul private aviation activity grows.
Volato Group (NYSE American: SOAR) announced the commercial launch of Volato AI, a purpose-built enterprise AI platform for business aviation, and its first enterprise deployment with Flyte, a regional air mobility company owned by Catheter Precision (NYSE American: VTAK). The aviation-specific AI agents are designed to increase employee productivity, improve customer responsiveness, reduce administrative workload, and help operators scale Part 135 charter operations without proportional overhead growth.
The initial Flyte deployment will cover workflows such as customer communications, charter sales support, flight quoting, crew coordination, maintenance scheduling, dispatch support, compliance assistance, document management, and administrative automation. Volato emphasized that its pending AI infrastructure business combination remains the company’s primary strategic focus and is still subject to due diligence, definitive agreements, and regulatory and exchange requirements.